NIH funding by institute · Fiscal year 2026
National Cancer Institute (NCI) Grants and Funding
Reviewed by Dr. Meng ZhaoLast reviewed October 26, 2026Data refreshed October 16, 2026Editorial standards
NCI administered $4.43B in fiscal year 2026 across 6,803 award records to 244 institutions with $10M or more in NIH funding, down 7.9% from FY2025. University of Texas MD Anderson Cancer Center received the most, 3.6% of that total.
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
FY2026 NCI funding
$4.43B
−7.9% vs FY2025
Award records
6,803
Institutions funded
244
Recipients with $10M+ in NIH funding
Open or upcoming NOFOs
123
NCI as lead or participating institute
Top NCI-funded institutions, FY2026
| # | Institution | NCI FY2026 | vs FY2025 | Awards | Share |
|---|---|---|---|---|---|
| 1 | University of Texas MD Anderson Cancer CenterHouston, TX | $157.9M | −9.4% | 239 | 3.6% |
| 2 | Sloan Kettering Institute for Cancer ResearchNew York, NY | $149.0M | +4.6% | 207 | 3.4% |
| 3 | Dana-Farber Cancer InstituteBoston, MA | $133.2M | −2.0% | 174 | 3.0% |
| 4 | University of California, San FranciscoSan Francisco, CA | $114.5M | −8.0% | 169 | 2.6% |
| 5 | Fred Hutchinson Cancer CenterSeattle, WA | $112.6M | −9.4% | 109 | 2.5% |
| 6 | Washington University in St. LouisSaint Louis, MO | $98.3M | +0.5% | 160 | 2.2% |
| 7 | University of MichiganAnn Arbor, MI | $94.1M | +6.6% | 157 | 2.1% |
| 8 | University of PennsylvaniaPhiladelphia, PA | $93.8M | +1.6% | 156 | 2.1% |
| 9 | Johns Hopkins UniversityBaltimore, MD | $90.2M | −0.5% | 145 | 2.0% |
| 10 | Stanford UniversityStanford, CA | $83.7M | −6.6% | 141 | 1.9% |
| 11 | Columbia University Health SciencesNew York, NY | $80.4M | +8.1% | 125 | 1.8% |
| 12 | Massachusetts General HospitalBoston, MA | $80.1M | −3.1% | 133 | 1.8% |
| 13 | Icahn School of Medicine at Mount SinaiNew York, NY | $79.9M | +0.4% | 93 | 1.8% |
| 14 | Mayo Clinic RochesterRochester, MN | $74.3M | +10.9% | 91 | 1.7% |
| 15 | University of North Carolina at Chapel HillChapel Hill, NC | $72.0M | +1.6% | 112 | 1.6% |
| 16 | UT Southwestern Medical CenterDallas, TX | $70.7M | +8.0% | 106 | 1.6% |
| 17 | NYU Grossman School of MedicineNew York, NY | $69.8M | +19.4% | 103 | 1.6% |
| 18 | Yale UniversityNew Haven, CT | $67.6M | +2.0% | 121 | 1.5% |
| 19 | The Ohio State UniversityColumbus, OH | $61.7M | +0.2% | 95 | 1.4% |
| 20 | Northwestern UniversityChicago, IL | $60.5M | −0.3% | 96 | 1.4% |
| 21 | University of PittsburghPittsburgh, PA | $60.5M | −10.7% | 110 | 1.4% |
| 22 | Emory UniversityAtlanta, GA | $55.6M | +24.0% | 97 | 1.3% |
| 23 | University of California San DiegoLa Jolla, CA | $55.2M | +19.1% | 88 | 1.2% |
| 24 | University of Wisconsin-MadisonMadison, WI | $55.1M | +16.3% | 77 | 1.2% |
| 25 | Duke UniversityDurham, NC | $52.7M | −11.7% | 112 | 1.2% |
Showing the 25 largest of 244 institutions with NCI funding.
Open and upcoming NCI funding opportunities
NOFOs led by NCI first, then those NCI participates in, soonest due date first. Browse every NIH NOFO.
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
RFA-CA-27-001 · R61
Next due Nov 10, 2026
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
RFA-CA-27-002 · R33
Next due Nov 10, 2026
- Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)
PAR-25-336 · R01
Next due Nov 16, 2026
- Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)
PAR-28-022 · P50 · opens soon
Next due Jan 25, 2027
- Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed)
PAR-28-057 · U24 · opens soon
Next due Jan 25, 2027
- Cancer Advancement through Partnerships in Research and Infrastructure (CAPRI) (U54 Clinical Trial Optional)
PAR-28-062 · U54 · opens soon
Next due Jan 25, 2027
- Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)
PAR-25-444 · P30
Next due Jan 25, 2027
- Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)
PAR-25-325 · U01
Next due Feb 4, 2027
- Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)
PAR-28-056 · U01 · opens soon
Next due Feb 5, 2027
Next due Feb 5, 2027
- Research Opportunities in Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)
PAR-27-073 · U01
Next due Feb 5, 2027
- Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
PAR-25-337 · R01
Next due Feb 5, 2027
- Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)
PAR-25-338 · R01
Next due Feb 5, 2027
Next due Feb 5, 2027
Next due Feb 5, 2027
Showing 15 of 123. See all NCI NOFOs.
Recent NCI awards
The newest NCI award notices among the institutions above, each linked to its NIH RePORTER record.
- Patient-Derived Models to Identify Effective Therapies in Aggressive Large B-Cell Lymphomas (opens NIH RePORTER)
Massachusetts General Hospital · 1R01CA309104-01A1 · NCI · Notice Sep 24, 2026
$600KR01
- Extracellular Vesicle Cargoes as Diagnostic and Prognostic Biomarkers of Malignant Pleural Effusion (opens NIH RePORTER)
Vanderbilt University Medical Center · 1R01CA316439-01 · NCI · Notice Sep 23, 2026
$726KR01
- Targeting Lactylation of Critical Drivers in Neuroendocrine Prostate Cancer for Therapy (opens NIH RePORTER)
University of Kentucky · 1R37CA311186-01 · NCI · Notice Sep 23, 2026
$453KR37
- Overcoming ovarian cancer chemoresistance by co-targeting senescence and apoptosis (opens NIH RePORTER)
Harvard T.H. Chan School of Public Health · 1R01CA311522-01 · NCI · Notice Sep 23, 2026
$390KR01
- Elucidation of a post-transcriptional regulatory node in macrophage function (opens NIH RePORTER)
University of California, San Francisco · 1DP2CA325959-01 · NCI · Notice Sep 22, 2026
$766KDP2
- Anti-tumor immunity via IL-12 delivery in the tumor microenvironment (opens NIH RePORTER)
Harvard University · 1R01CA308075-01A1 · NCI · Notice Sep 22, 2026
$641KR01
- SOMATIC EVOLUTION AND PRE-CANCER OF TP53 MUTANT CLONES (opens NIH RePORTER)
Baylor College of Medicine · 1R21CA317193-01 · NCI · Notice Sep 22, 2026
$429KR21
- Tackling tumor recurrence in pediatric brain tumors: identification of epigenetic memory and tumor microenvironment conducive to tumor recurrence in an inducible and reversible H3K27M murine model. (opens NIH RePORTER)
University of Michigan · 1R21CA308699-01A1 · NCI · Notice Sep 22, 2026
$401KR21
- High Throughput Profiling of the In Vivo Tumor Neo-antigen Specific Antibody Reactivity Landscape using PhIP-Seq (opens NIH RePORTER)
University of Maryland, Baltimore · 1R03CA304848-01A1 · NCI · Notice Sep 22, 2026
$156KR03
- Rationally directed therapy for CLL (opens NIH RePORTER)
University of Texas MD Anderson Cancer Center · 1R01CA309939-01A1 · NCI · Notice Sep 21, 2026
$690KR01
Looking for a postdoc in cancer research?
See how many cancer research labs received a new NCI R01 or R00 in the last three months, by month, state, and institution.
Newly funded cancer research labsQuestions about NCI funding
- How much does NCI fund?
- In fiscal year 2026, NCI administered $4.43B across 6,803 award records to the 244 institutions on this page. These are the recipients with $10M or more in total NIH funding, so the figure is a large share of NCI's extramural awards but not its full budget.
- Which institutions get the most NCI funding?
- University of Texas MD Anderson Cancer Center ($157.9M), Sloan Kettering Institute for Cancer Research ($149.0M), Dana-Farber Cancer Institute ($133.2M) led NCI funding in FY2026.
- How do I find an open NCI funding opportunity?
- This page lists open and upcoming NOFOs where NCI is the lead or a participating institute, with the next due date. Most investigator-initiated applications go through the NIH parent announcements instead, and are assigned to an institute after submission; contact a NCI program officer before you apply to check fit.
More NIH funding rankings
By type
University and health systems
By NIH institute
All institutes · NIAID · NIA · NHLBI · NIGMS · NINDS · NIDDK · NIMH · OD · NICHD · NIDA · NCATS · NEI · NIAMS · NIEHS · NHGRI · NIAAA · NIDCD · NIDCR · NIBIB · NIMHD · NCCIH · NINR · NLM · FIC
By state
California · New York · Massachusetts · Pennsylvania · Texas · North Carolina · Maryland · Illinois · Washington · Ohio · Michigan · Florida · Missouri · Connecticut · Georgia · Minnesota · Tennessee · Wisconsin · Virginia · Colorado · New Jersey · Indiana · Oregon · Arizona · Alabama · Utah · Rhode Island · South Carolina · Kentucky · District of Columbia · Louisiana · Iowa · Oklahoma · Kansas · Nebraska · New Hampshire · New Mexico · Maine · Arkansas · Delaware · Mississippi · Vermont · Hawaii · Montana · West Virginia · Puerto Rico · South Dakota · Nevada · Idaho · North Dakota · Alaska · Wyoming